![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Removes Clinical Hold on RespireRX’s CX1739
FDA Removes Clinical Hold on RespireRX’s CX1739
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
March 4, 2016
The FDA removed a clinical hold on RespireRx Pharmaceuticals’ experimental drug CX1739.
The agency placed the hold in December 2015 after toxicity was seen in animal studies. The company subsequently conducted an additional safety study and was cleared to resume trials.
The drugmaker plans to begin Phase 2a clinical trials in March for the treatment of opioid-induced respiratory depression.
Upcoming Events
-
21Oct